Download PDF
Endoscopy 2008; 40(10): 823-827
DOI: 10.1055/s-2008-1077568
DDW highlights

© Georg Thieme Verlag KG Stuttgart · New York

Reflux disease and Barrett’s esophagus

J.  A.  Abrams1 , 2 , C.  J.  Lightdale1 , 2
  • 1Division of Digestive and Liver Disease, Columbia University Medical Center, New York, New York, USA
  • 2Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA
Further Information

Publication History

Publication Date:
30 September 2008 (online)

Also available at
    Permissions and Reprints

Introduction

Despite the high prevalence of gastroesophageal reflux disease (GERD) and, to a lesser degree, Barrett’s esophagus in the Western world, there are still many unknowns with regard to the epidemiology, natural history, and appropriate treatments for these conditions. There is a significant amount of ongoing research into endoscopic treatment modalities in an attempt to reduce the need for medical therapy for GERD. Meanwhile, the underlying biology of Barrett’s carcinogenesis is incompletely understood, as is the ideal treatment for Barrett’s esophagus and advanced neoplasia.

References

  • 1 Pace F, Bollani S, Molteni P. et al . Natural history of gastro-oesophageal reflux disease without oesophagitis (NERD) – a reappraisal 10 years on.  Dig Liver Dis. 2004;  36 111-115
    CrossrefPubMedSearch in Google Scholar
  • 2 Locke 3rd G R. Natural history of nonerosive reflux disease. Is all gastroesophageal reflux disease the same? What is the evidence?.  Gastroenterol Clin North Am. 2002;  31 S59-S66
    PubMedSearch in Google Scholar
  • 3 Ronkainen J, Aro P, Storskrubb T. et al . Natural history of NERD in the general population, the Kalixanda study.  Gastroenterology. 2008;  134 A74
    PubMedSearch in Google Scholar
  • 4 El-Serag H. Role of obesity in GORD-related disorders.  Gut. 2008;  57 281-284
    CrossrefPubMedSearch in Google Scholar
  • 5 Ruhl C E, Everhart J E. Overweight, but not high dietary fat intake, increases risk of gastroesophageal reflux disease hospitalization: the NHANES I Epidemiologic Followup Study. First National Health and Nutrition Examination Survey.  Ann Epidemiol. 1999;  9 424-435
    CrossrefPubMedSearch in Google Scholar
  • 6 El-Serag H B, Petersen N J, Carter J. et al . Gastroesophageal reflux among different racial groups in the United States.  Gastroenterology. 2004;  126 1692-1699
    CrossrefPubMedSearch in Google Scholar
  • 7 Singson Z, Vega K, Jamal M M. Trends in the endoscopic spectrum of GERD among a large cohort of patients.  Gastroenterology. 2008;  134 A39
    CrossrefPubMedSearch in Google Scholar
  • 8 Jazrawi S, Walsh T N, Byrne P J. et al . Cholecystectomy and oesophageal reflux: a prospective evaluation.  Br J Surg. 1993;  80 50-53
    CrossrefPubMedSearch in Google Scholar
  • 9 McNamara D A, O’Donohoe M K, Horgan P G. et al . Symptoms of oesophageal reflux are more common following laparoscopic cholecystectomy than in a control population.  Ir J Med Sci. 1998;  167 11-13
    PubMedSearch in Google Scholar
  • 10 Maddern G J, Baxter P S. The effect of laparoscopic cholecystectomy on gastroduodenal reflux.  Aust N Z J Surg. 1997;  67 703-705
    PubMedSearch in Google Scholar
  • 11 Manifold D K, Anggiansah A, Owen W J. Effect of cholecystectomy on gastroesophageal and duodenogastric reflux.  Am J Gastroenterol. 2000;  95 2746-2750
    PubMedSearch in Google Scholar
  • 12 Lin O, Kozarek R A. The association between cholecystectomy and gastroesophageal reflux symptoms.  Gastrointest Endosc. 2008;  67 AB85
    PubMedSearch in Google Scholar
  • 13 Aanen M C, Weusten B L, Numans M E. et al . Diagnostic value of the proton pump inhibitor test for gastro-oesophageal reflux disease in primary care.  Aliment Pharmacol Ther. 2006;  24 1377-1384
    CrossrefPubMedSearch in Google Scholar
  • 14 des Varannes S B, Sacher-Huvelin S, Vavasseur F. et al . Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting.  World J Gastroenterol. 2006;  12 2569-2573
    PubMedSearch in Google Scholar
  • 15 Numans M E, Lau J, de Wit N J. et al . Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics.  Ann Intern Med. 2004;  140 518-527
    CrossrefPubMedSearch in Google Scholar
  • 16 Bytzer P, Jones R, Vakil N. et al . Evaluation of the proton pump inhibitor (PPI) test for the diagnosis of GERD: Results from the Diamond study.  Gastroenterology. 2008;  134 A100
    PubMedSearch in Google Scholar
  • 17 Morana E, Guida L, Cavallaro L G. et al . Gastrin-17 (G-17): a serological bio-marker for diagnosis of gastro-esophageal reflux disease (GERD).  Gastroenterology. 2008;  134 A101
    PubMedSearch in Google Scholar
  • 18 Monkemuller K, Neumann H, Nocon M. et al . Serum gastrin and pepsinogens do not correlate with the different grades of severity of GERD: a matched case-control study.  Aliment Pharmacol Ther. 2008;  in press
    PubMedSearch in Google Scholar
  • 19 Demaria E J, Jamal M K. Surgical options for obesity.  Gastroenterol Clin North Am. 2005;  34 127-142
    CrossrefPubMedSearch in Google Scholar
  • 20 Pohl D, Mueller M K, Wildi S. et al . Gastroesophageal reflux and esophageal peristalsis before and after gastric bypass surgery – an interim analysis of combined impedance-pH and high resolution manometry data.  Gastroenterology. 2008;  134 A13
    PubMedSearch in Google Scholar
  • 21 Kubo A, Corley D A. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis.  Cancer Epidemiol Biomarkers Prev. 2006;  15 872-878
    CrossrefPubMedSearch in Google Scholar
  • 22 Vakil N. Review article: the role of surgery in gastro-oesophageal reflux disease.  Aliment Pharmacol Ther. 2007;  25 1365-1372
    CrossrefPubMedSearch in Google Scholar
  • 23 Lundell L. Therapy of gastroesophageal reflux: evidence-based approach to antireflux surgery.  Dig Dis. 2007;  25 188-196
    CrossrefPubMedSearch in Google Scholar
  • 24 Hatlebakk J G, Lundell L R, Galmiche J P. et al . Initial control of acid reflux after laparoscopic anti-reflux surgery (LARS) compared to chronic use of esomeprazole (ESO) 20 – 40 mg daily.  Gastroenterology. 2008;  134 A125
    PubMedSearch in Google Scholar
  • 25 Pleskow D, Rothstein R, Kozarek R. et al . Endoscopic full-thickness plication for the treatment of GERD: five-year long-term multicenter results.  Surg Endosc. 2008;  22 326-332
    CrossrefPubMedSearch in Google Scholar
  • 26 Pleskow D, Rothstein R, Kozarek R. et al . Endoscopic full-thickness plication for the treatment of GERD: long-term multicenter results.  Surg Endosc. 2007;  21 439-444
    CrossrefPubMedSearch in Google Scholar
  • 27 Corsetti M, Passaretti S M, Di Pietro S. et al . Effect of the EsophyX device for endoluminal fundoplication on symptoms, esophageal manometry and pH-impedence of patients with gastro-esophageal reflux.  Gastroenterology. 2008;  134 A13
    PubMedSearch in Google Scholar
  • 28 Wong A, Fitzgerald R C. Epidemiologic risk factors for Barrett’s esophagus and associated adenocarcinoma.  Clin Gastroenterol Hepatol. 2005;  3 1-10
    CrossrefPubMedSearch in Google Scholar
  • 29 de Jonge P J, van Blankenstein M, Looman C W. et al . Trends in the incidence of Barrett’s esophagus in the Netherlands 1991 – 2006.  Gastroenterology. 2008;  134 A39
    CrossrefPubMedSearch in Google Scholar
  • 30 Conio M, Blanchi S, Lapertosa G. et al . Long-term endoscopic surveillance of patients with Barrett’s esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study.  Am J Gastroenterol. 2003;  98 1931-1939
    CrossrefPubMedSearch in Google Scholar
  • 31 Drewitz D J, Sampliner R E, Garewal H S. The incidence of adenocarcinoma in Barrett’s esophagus: a prospective study of 170 patients followed 4.8 years.  Am J Gastroenterol. 1997;  92 212-215
    PubMedSearch in Google Scholar
  • 32 Sikkema M, Kerkhof M, Steyerberg E W. et al . Prospective multicenter study on the incidence of neoplastic progression in Barrett esophagus patients.  Gastrointest Endosc. 2008;  67 AB75
    PubMedSearch in Google Scholar
  • 33 Wang K K, Sampliner R E. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus.  Am J Gastroenterol. 2008;  103 788-797
    CrossrefPubMedSearch in Google Scholar
  • 34 McCallum A L, Macpherson M, Jenkins J T. et al . Autofluorescence assessment in the surveillance of Barrett’s oesophagus: a randomised trial comparing standard 4 quadrant biopsy and AF directed biopsy.  Gastroenterology. 2008;  134 A63
    PubMedSearch in Google Scholar
  • 35 Wolfsen H C, Crook J E, Krishna M. et al . Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barrett’s esophagus.  Gastroenterology. 2008;  135 24-31
    CrossrefPubMedSearch in Google Scholar
  • 36 Dunbar K B, Montgomery E A, Okolo P. et al . Confocal laser endomicroscopy in Barrett’s esophagus and associated neoplasia: a prospective randomized controlled crossover trial.  Gastrointest Endosc. 2008;  67 AB97
    PubMedSearch in Google Scholar
  • 37 Reid B J, Blount P L, Rabinovitch P S. Biomarkers in Barrett’s esophagus.  Gastrointest Endosc Clin N Am. 2003;  13 369-397
    PubMedSearch in Google Scholar
  • 38 Sikkema M, Kerkhof M, Steyerberg E W. et al . Flow cytometry in Barrett esophagus (Cybar Study): a prospective cohort study.  Gastroenterology. 2008;  134 A110
    PubMedSearch in Google Scholar
  • 39 Spechler S J. Barrett’s esophagus: a molecular perspective.  Curr Gastroenterol Rep. 2005;  7 177-181
    CrossrefPubMedSearch in Google Scholar
  • 40 Berman D M, Karhadkar S S, Maitra A. et al . Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours.  Nature. 2003;  425 846-851
    CrossrefPubMedSearch in Google Scholar
  • 41 Oh D S, DeMeester S R, Mori R. et al . Sonic Hedgehog gene expression in Barrett’s esophagus and esophageal adencoarcinoma.  Gastroenterology. 2008;  134 A150
    PubMedSearch in Google Scholar
  • 42 Shaheen N J, Sharma P, Overholt B F. et al . A randomized, multicenter, sham-controlled trial of radiofrequency ablation (RFA) for subjects with Barrett’s esophagus (BE) containing dysplasia: interim results of the AIM Dysplasia Trial.  Gastroenterology. 2008;  134 A37
    PubMedSearch in Google Scholar
  • 43 Reed M F, Tolis Jr G, Edil B H. et al . Surgical treatment of esophageal high-grade dysplasia.  Ann Thorac Surg. 2005;  79 1110-1115; discussion 1110 – 1115
    CrossrefPubMedSearch in Google Scholar
  • 44 Konda V J, Chennat J S, Ross A S. et al . Low rate of invasive cancer in patients undergoing mucosectomy for Barrett’s esophagus (BE) and high grade dysplasia (HGD) or intramucosal carcinoma (IMC).  Gastrointest Endosc. 2008;  67 AB76
    PubMedSearch in Google Scholar
  • 45 Conio M, Ponchon T, Blanchi S. et al . Endoscopic mucosal resection.  Am J Gastroenterol. 2006;  101 653-663
    CrossrefPubMedSearch in Google Scholar
  • 46 Manner H, May A, Pech O. et al . Are patients with ”low risk“ submucosal invasion of early Barrett’s carcinoma eligible for curative endoscopic therapy? Outcomes of endoscopic therapy and surgery in 80 patients with suspected or definite diagnosis of submucosal Barrett’s cancer.  Gastrointest Endosc. 2008;  67 AB75
    PubMedSearch in Google Scholar

C. J. LightdaleMD 

Columbia University Medical Center

180 Ft. Washington Ave.
Harkness Pavilion 7-712
New York
NY 10032
USA

Fax: +1-212-3059913

Email: cjl18@columbia.edu